Although clinical trials have failed to show their efficacy, a recent reanalysis of these studies suggested that these drugs may benefit AD patients with potentially greater therapeutic efficacy in those homozygous for the APOE ε4 allele (Storck and Pietrzik, 2017), though it is not known whether the modulation of LRP-1 plays any role. The gene discussed is APOE; the disease is Alzheimer disease.